MedPath

NEPHRON PHARMACEUTICALS CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

9

FDA:7
CANADA:1

Drug Approvals

Ipratropium Bromide and Albuterol Sulfate

Approval Date
Jan 10, 2024
FDA

Sterile Water

Approval Date
Jun 4, 2021
FDA

Albuterol Sulfate

Approval Date
Jan 11, 2021
FDA

Budesonide

Approval Date
Jan 11, 2021
FDA

Albuterol Sulfate

Approval Date
Jan 11, 2021
FDA

Ipratropium Bromide

Approval Date
Jan 11, 2021
FDA

Albuterol Sulfate

Approval Date
Jan 11, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
First Posted Date
2021-03-04
Last Posted Date
2021-05-10
Lead Sponsor
Nephron Pharmaceuticals Corporation
Target Recruit Count
116
Registration Number
NCT04780984
Locations
🇺🇸

Clinical Research of Rock Hill, Rock Hill, South Carolina, United States

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Primary Open Angle Glaucoma
Ocular Hypertension
Interventions
First Posted Date
2014-02-11
Last Posted Date
2018-08-22
Lead Sponsor
Nephron Pharmaceuticals Corporation
Target Recruit Count
335
Registration Number
NCT02059278

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.